This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The three strategies were full-night polysomnography, split-night polysomnography, and unattended portable home monitoring. Diagnosed patients were treated with CPAP. A fourth strategy was considered, in which all patients were titrated and then treated with CPAP, and a fifth strategy was no diagnosis and no treatment.
Full-night polysomnography was conducted overnight in a laboratory and CPAP titration was performed on a subsequent night in the laboratory, if the criteria for obstructive sleep apnoea were met. Split-night polysomnography was performed in the laboratory over the first two hours, with the remainder of the night spent in CPAP titration for patients who met the criteria or polysomnography continued for the whole night for patients who did not meet the criteria in the first two hours, with titration on a subsequent night if the criteria were met.
Results
In a hypothetical cohort of 50-year-old men, the lifetime costs were $216,934 with no treatment and $243,656 with CPAP treatment. The life-years were 16.062 with no treatment and 17.165 with CPAP. The QALYs were 10.814 with no treatment and 12.493 with CPAP. The incremental cost with CPAP over no treatment was $24,222 per life-year gained or $15,915 per QALY gained.
Over 10 years, the incremental cost was $102,585 per life-year gained or $16,172 per QALY gained.
Comparing diagnostic strategies, the lifetime costs were $217,602 with no intervention, $231,553 with full-night polysomnography, $232,060 with split-night polysomnography, $232,716 with home monitoring, and $243,879 with treatment for all. The life-years were 16.7920 with no intervention, 17.3271 with full-night polysomnography, 17.3271 with split-night polysomnography, 17.3061 with home monitoring, and 17.3436 with treatment for all. The QALYs were 12.3600 with no intervention, 13.1743 with full-night polysomnography, 13.1683 with split-night polysomnography, 13.1269 with home monitoring, and 13.0994 with treatment for all.
The incremental cost per QALY gained analysis showed that split-night polysomnography, home monitoring, and treatment for all were dominated, as they were more expensive and less effective than full-night polysomnography. The incremental cost for full-night polysomnography, compared with no intervention was $26,073 per life-year gained or $17,131 per QALY gained.
In general, these findings were robust to the variations considered in the sensitivity analyses. Slightly less favourable cost-effectiveness estimates were observed for women than for men. The cost-effectiveness of diagnosis depended on the cost-effectiveness of treatment.
